NCT00471965 - Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients | Biotech Hunter

Enrollment

371

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Oxaliplatin + 5-Fluorouracil/Leucovorin

"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"

DRUG

Doxorubicin

Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.

Trial Locations (4)

Unknown

Sanofi-Aventis Administrative Office, Shanghai

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Bangkok